Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Joseph Caravaglio

Dermatology Jacksonville, FL Medical Doctor

NPI 1164953832 CMS profile 9714286

14810 Old Saint Augustine Rd Ste 103, Jacksonville, FL 32258

Open in the dashboard

General payments

$50,681

294 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joseph Caravaglio of Jacksonville, FL is reported in the CMS Open Payments database as having received $50,681 across 294 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $39,629 118
2024 General $8,674 55
2023 General $1,362 71
2022 General $768 37
2021 General $249 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joseph Caravaglio
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Joseph Caravaglio were reported at $39,629. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Joseph Caravaglio Dermatology median Middle half National median
2019 $0 $454 $129–$1,240 $163
2020 $0 $235 $81–$756 $114
2021 $249 $377 $108–$1,108 $132
2022 $768 $514 $143–$1,391 $149
2023 $1,362 $607 $159–$1,674 $160
2024 $8,674 $751 $204–$1,903 $164
2025 $39,629 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $25,923 45 payments
  2. Janssen Biotech, Inc. $20,149 43 payments
  3. E.R. Squibb & Sons, L.L.C. $410 10 payments
  4. Pfizer Inc. $378 25 payments
  5. Genzyme Corporation $363 15 payments
  6. Novartis Pharmaceuticals Corporation $361 16 payments
  7. Regeneron Healthcare Solutions, Inc. $339 12 payments
  8. Sun Pharmaceutical Industries Inc. $323 17 payments
  9. UCB, Inc. $320 13 payments
  10. Arcutis Biotherapeutics, Inc. $266 14 payments
  11. Other $1,850 84 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $38,378 15 payments
  2. Food and Beverage $7,256 271 payments
  3. Travel and Lodging $4,833 5 payments
  4. Education $214 3 payments
Products named General payments · program years 2021–2025
  1. RINVOQ $25,762 34 payments
  2. TREMFYA $20,149 43 payments
  3. DUPIXENT Immunology $517 21 payments
  4. SOTYKTU $410 10 payments
  5. CIBINQO $358 24 payments
  6. Tolak $253 1 payment
  7. DUPIXENT Inflammation And Immunology $251 9 payments
  8. Bimzelx $225 10 payments
  9. Otezla $217 9 payments
  10. OPZELURA $216 8 payments
  11. Other $2,976 157 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

329

Median for Dermatology: 534

Drug cost

$7,914

Median for Dermatology: $67,151

Branded share of claims

0%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Fluorouracil Generic 50 $3,124
Ketoconazole Generic 98 $1,580
Clobetasol Propionate Generic 36 $1,254
Metronidazole Generic 11 $675
Triamcinolone Acetonide Generic 43 $409
Clindamycin Phosphate Generic 14 $344
Doxycycline Hyclate Generic 22 $197
Mupirocin Generic 21 $173
Hydrocortisone Generic 34 $160

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$106,430

Medicare's payments for the services billed

Medicare patients

305

Average age 75

Services billed

2,146

123 women, 182 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 43%
Ischemic heart disease 32%
Chronic kidney disease 24%
Diabetes 23%
Atrial fibrillation 15%
Depression 14%
Osteoporosis 12%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $7,501
$7,501 — —
RINVOQ
  • AbbVie, Inc. $376
$376 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $310
$310 — —
OPZELURA
  • Incyte Corporation $66
$66 — —
Zoryve
  • Arcutis Biotherapeutics, Inc. $51
$51 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

294 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record